The Latest Progress of Targeting Fibroblast Activating Protein PET/CT Molecular Imaging in Heart Failure

Read full text Summarise with VIRAT
Authors: Haoran Guo, Jianming Li
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Heart failure (HF), the devastating end-stage manifestation of numerous cardiovascular diseases, exhibits alarmingly high morbidity, recurrent hospitalization rates, and mortality. At the core of this pathology lies myocardial fibrosis. Early detection, precise classification, dynamic monitoring, and rigorous assessment of treatment response for myocardial fibrosis are crucial for advancing precision management of HF. In recent years, fibroblast activation protein (FAP)-targeted molecular imaging—specifically fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT)—has garnered considerable attention. This innovative technology uniquely enables the visualization and quantitative assessment of myocardial fibrosis at the molecular level. This review synthesizes the latest research progress on FAPI PET/CT in HF, emphasizing its promising potential for application in the early diagnosis, risk stratification, and prediction of outcomes related to myocardial fibrosis. It also critically examines existing technical limitations and explores prospects for future research.

Fields of Study & Subjects

Peptidase Inhibition and Analysis Cardiac Imaging and Diagnostics Cardiac Fibrosis and Remodeling

Publication details

Journal / source
iCirculation
Volume
1
Issue
1
Publication date
18 March 2026
Language
EN